Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
Although much remains unknown about coronavirus disease 2019 (COVID-19), knowledge is expanding every hour, and many healthcare providers, overwhelmed by infected patients and a struggling healthcare infrastructure, are unable to keep up with the changing landscape. Furthermore, the lag in peer-reviewed publication timelines means that the most critical information, when not disseminated by the Centers for Disease Control and Prevention (CDC) or national and international organizations, will be distributed by mainstream media through social media platforms, interspersed with false, contradictory, or misleading information, thereby presenting additional time-consuming challenges to clinicians. The rapidly evolving nature of the pandemic necessitates the dissemination of up-to-date information through continuing education programs in order to ensure healthcare providers are optimally prepared to care for patients.
With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines authorized or close to authorization. This educational activity will provide clinicians a review of the FDA’s guidance on vaccine approval and emergency use authorization (EUA), up-to-date safety and efficacy information on vaccine candidates in late-stage development.
This is a Twitter-based tutorial designed to provide key information in an accessible format and location.
Michael Mina, MD, PhD
Assistant Professor, Epidemiology & Immunology
Harvard T. H. Chan School of Public Health
Associate Medical Director, Pathology
Brigham & Woman’s Hospital
Harvard Medical School
Onyema Ogbuagu, MD, FACP
Associate Professor of Medicine
Director, HIV Clinical Trials
Section of Infectious Diseases
Yale University School of Medicine
New Haven, Connecticut
This program is intended for infectious disease experts, immunologists, geriatricians, primary care physicians, nurse practitioners, physician’s assistants, nurses, and other members of the healthcare team involved in, or interested in, education regarding COVID-19 vaccines.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of March 2, 2021 through March 2, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or email@example.com.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Michael J. Mina, MD, PhD
Consulting Fees: Detect Diagnostics
Onyema Ogbuagu, MD, FACP
Consulting Fees: Gilead Sciences, ViiV
Speakers’ Bureaus: Gilead Sciences
The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.